Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.4K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

6.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.4K
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

6.9K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
6.9K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

5.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
5.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the Pediatric Type 2 Diabetes Impact Measure (P-TIM).

Journal of patient-reported outcomes·2026
Same author

Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight.

Advances in therapy·2026
Same author

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Differences in Perspectives of Weight Management Among People in the US and Canada with Type 2 Diabetes by Body Mass Index.

Patient preference and adherence·2026
Same author

The Value and Impact of Weight Reduction from the Perspective of People in Canada with Type 2 Diabetes.

Advances in therapy·2026
Same author

Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.

Annals of internal medicine·2026

Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K

A model of mild hypoglycemia.

Stuart Samuel1, Devesh Goswami, Kenny Shum

  • 1Evidera , San Francisco, CA , USA.

Current Medical Research and Opinion
|February 19, 2015
PubMed
Summary

Mild hypoglycemia affects US patients with type 2 diabetes (T2DM), with insulin users experiencing higher rates. This condition incurs significant economic costs, comparable to severe hypoglycemia.

Keywords:
Archimedes ModelHypoglycemiaMild hypoglycemiaModelType 2 diabetes

More Related Videos

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

994
A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

994
A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacoeconomics

Background:

  • Type 2 diabetes (T2DM) management requires balancing glycemic control with hypoglycemia risks.
  • Mild hypoglycemia is a common complication in T2DM patients, impacting quality of life and healthcare costs.

Purpose of the Study:

  • To quantify the incidence of mild hypoglycemia in US T2DM patients.
  • To identify key risk factors associated with mild hypoglycemia.
  • To estimate the economic burden of mild hypoglycemia in the US.

Main Methods:

  • A literature search was conducted to gather data on mild hypoglycemia rates.
  • A mathematical model was developed to predict hypoglycemia rates based on patient characteristics and treatments.
  • Model inputs included antidiabetic medications, HbA1c, diabetes duration, kidney function, and BMI.

Main Results:

  • The average rate of mild hypoglycemia was estimated at 2.2 events per person per year.
  • Insulin users had higher rates (4.9 events/person/year) compared to oral medication users (1.9 events/person/year).
  • Mild hypoglycemia rates increased with age, and the estimated annual economic impact was approximately $900 million.

Conclusions:

  • A validated model can help identify T2DM patients at high risk for hypoglycemia.
  • Understanding hypoglycemia risks and costs is crucial for effective T2DM management.
  • The model aids researchers, clinicians, and payers in assessing individual patient risk and economic burden.